Floatz logo

INSULIN GLARGINE (SANOFI)

Leukemia

University of Medicine and Dentistry of New Jerseyprotein_peptidePhase 3Dormant
CCC
49/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
65/ 100

Competitive context

123 Active assets in the Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
Inhye Ahn
Phase 3BB
PEGASPARGASE
Dana-Farber Cancer Institute
Phase 3BB
MERCAPTOPURINE ANHYDROUS
Dana-Farber Cancer Institute
Phase 3BB
FILGRASTIM
Hospital General de Mexico
Phase 4BB
Daunorubicin
Richard Stone, MD
Phase 3BB

View all 50 →

Same molecule, other indications

INSULIN GLARGINE (SANOFI) is also rated in:

Diabetes Mellitus, Type 2Dormant
BB
Indicative ·
66 / 100
View asset →
HyperglycemiaDormant
B
Indicative ·
63 / 100
View asset →
Non-alcoholic Fatty Liver DiseaseDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →